A better quarterly than most probably expected. A clear route of where we are headed in 2017 and everything is on schedule. Plenty of cash in reserve as Clarko just mentioned so no further CR required for a long time. 84%-100% success rate is well above what would be required to surpass the abbey scale method and become the standard. Still on track for Q3 submission of FDA approval. Tomorrow could be an interesting days trade!
Ann: Second Quarter Report FY 2016/17, page-4
-
- There are more pages in this discussion • 209 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
